Since the time of the discovery, a large progress has been made in discerning the role of RAGE–Diaph1 signaling in neuroinflammation and hyperglycemia, and a number of small-molecule RAGE–Diaph1 inhibitors have been patented [40] allowing for both experimental and clinical studies. The gene discussed is DIAPH1; the disease is Hyperglycemia.